SCHEMBL24253472

SCHEMBL24253472

CCCc1ccc2c(c1F)CN(C)CC2

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
PNMT P11086 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
DRD2 P14416 3/20 0.36
DRD1 P21728 3/20 0.36
DRD5 P21918 3/20 0.36
DRD3 P35462 3/20 0.36
DRD4 P21917 1/20 0.36
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
HTR6 P50406 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14012987 0.78 MAOA (0.50) MAOAMAOBHTR2CHTR2BDRD2
SCHEMBL22993430 0.76 MAOA (0.46) MAOAMAOBDRD2DRD1DRD5
SCHEMBL24253322 0.72 MAOA (0.42) MAOAMAOBHTR2BDRD2DRD1
SCHEMBL14012989 0.69 MAOA (0.50) MAOAMAOBHTR2CHTR2BDRD2
SCHEMBL24253475 0.69 HTR2C (0.42) MAOAMAOBHTR2CHTR2BDRD2
SCHEMBL17345657 0.68 MAOA (0.53) MAOAMAOBHTR2CHTR2BDRD2
SCHEMBL24913963 0.68 MAOA (0.44) MAOAMAOBDRD2DRD1DRD5
SCHEMBL24253498 0.68 DRD2 (0.51) MAOAMAOBHTR2CHTR2BDRD2
SCHEMBL17719287 0.68 CTSL (0.45)
SCHEMBL22993389 0.67 DRD2 (0.49) MAOAMAOBHTR2CHTR2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 MAOA 175/4885MAOB 71/4885PNMT 2670/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 MAOA 175/4885MAOB 71/4885PNMT 2670/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 MAOA 175/4885MAOB 71/4885PNMT 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.